Finance

Lists
Outlook: 18.2% bullish·18.2% bearish
Go to analysis
NAGE:NASDAQ
Niagen Bioscience Inc
$2.07
-1.66%
(-0.035) 1D
Nov 6, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NAGE...
Open
$2.06
High
$2.11
Low
$2.04
Mkt. cap
165.09M
Avg. vol.
544.22K
Volume
463.38K
52-wk high
$7.28
52-wk low
$2.04
Beta
2.12
Shares outstanding
79.20M
No. of employees
117
Open
$2.06
High
$2.11
Low
$2.04
Mkt. cap
165.09M
Avg. vol.
544.22K
Volume
463.38K
52-wk high
$7.28
52-wk low
$2.04
Beta
2.12
Shares outstanding
79.20M
No. of employees
117
News stories
From web sources and news partners
Profile
Niagen Bioscience, formerly ChromaDex, is a bioscience сompany based in Los Angeles, California founded in 1999. The company operates in multiple sectors including reference standards, dietary supplements, and ingredient technology. Niagen Bioscience is publicly traded on the NASDAQ. Wikipedia
About Niagen Bioscience Inc
CEO-
Employees117
Founded1999
HeadquartersLos Angeles, California, United States
SectorConsumer Staples
IndustryPersonal care products
Websiteniagenbioscience.com
Analyst ratings
Based on 3 analysts giving stock ratings to NAGE in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for NAGE in the last 3 months.
Highest
Current $2.07
$10.00 (+383.09%)
Average
$9.00 (+334.78%)
Lowest
$7.00 (+238.16%)
Analyst
Recommendation
Action
Price target
Projected
Date
Susan Anderson
Canaccord Genuity
Buy
Maintained
$7.00
+238.2%
11/06/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$10.00
+383.1%
11/04/2026
Sean McGowan
Roth MKM
Buy
Maintained
$10.00
+383.1%
10/12/2026
Jeffrey Cohen
Ladenburg Thalmann & Co.
Buy
Maintained
$11.00
+431.4%
07/21/2026
Ilya Zubkov
Freedom Capital Markets
Buy
Initiated
$9.00
+334.8%
07/06/2026
Unknown Analyst
Ladenburg Thalmann & Co.
Buy
Reiterated
$12.00
+479.7%
05/07/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
33.84M
31.47M
29.78M
27.19M
Cost of goods sold
12.14M
11.50M
10.47M
10.09M
Cost of revenue
12.14M
11.50M
10.47M
10.09M
Research and development expenses
1.71M
1.48M
1.51M
1.80M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
17.89M
16.92M
17.10M
16.90M
Operating expense
19.60M
18.40M
18.61M
18.69M
Total operating expenses
31.74M
29.90M
29.08M
28.78M
Operating income
2.10M
1.58M
700.00K
-1.59M
Other non operating income
-214.00K
-
-
-
EBT including unusual items
4.42M
6.74M
1.07M
-1.17M
EBT excluding unusual items
2.44M
1.95M
1.07M
-1.17M
Income tax expense
292.00K
417.00K
106.00K
-
Effective tax rate
6.60%
6.19%
9.92%
-
Other operating expenses
-
-
-
-
Net income
4.13M
6.32M
963.00K
-1.17M
Net profit margin
12.21%
20.07%
3.23%
-4.31%
Earnings per share
0.03
0.02
0.01
-0.01
Interest and investment income
552.00K
375.00K
372.00K
414.00K
Interest expense
-
-
-
-
Net interest expenses
552.00K
375.00K
372.00K
414.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
2.30M
1.87M
991.00K
-1.30M
Gain or loss from assets sale
-
-4.78M
26.00K
3.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps